182496-01-1

Basic information

• Product Name: N-Benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-O-(2-methoxyethyl)-5-methylcytidine
• Synonyms: N-Benzoyl-2'-O-methoxyethyl-5-O-dimethoxytrityl-5-methylcytidine;N-Benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-O-(2-methoxyethyl)-5-methylcytidine;N-benzoyl-5'-O-DMTr-2'-O-(2-Methoxyethyl)-5-Methyl Cytidine;N4-Benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-O-(2-methoxyethyl)-5-methylcytidine;N-(1-((2R,3R,4R,5R)-5-((Bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxy-3-(2-methoxyethoxy)tetrahydrofuran-2-yl)-5-methyl-2-oxo-1,2-dihydropyrimidin-4-yl)benzamide;N4-Benzoyl-5'-O-DMT-2'-O-(2-Methoxyethyl)-5-methylcytidine
• CAS NO: 182496-01-1
• Molecular Formula: C₄₁H₄₃N₃O₉
• Molecular Weight: 722
• Mol File: 182496-01-1.mol
• Article Data: 385

Chemical Properties

• Appearance: /
• Density: 1.26
• PKA: 8.60±0.40(Predicted)
• CAS DataBase Reference: N-Benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-O-(2-methoxyethyl)-5-methylcytidine(CAS DataBase Reference)
• NIST Chemistry Reference: N-Benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-O-(2-methoxyethyl)-5-methylcytidine(182496-01-1)
• EPA Substance Registry System: N-Benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-O-(2-methoxyethyl)-5-methylcytidine(182496-01-1)

Safety Data

• Hazardous Substances Data: 182496-01-1(Hazardous Substances Data)

Usage

Description

N-Benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-O-(2-methoxyethyl)-5-methylcytidine is a protected form of cytidine, a naturally occurring nucleoside found in RNA. N-Benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-O-(2-methoxyethyl)-5-methylcytidine is characterized by the presence of a benzoyl group at the nitrogen atom, a bis(4-methoxyphenyl)phenylmethyl group at the 5' position, a 2-methoxyethyl group at the 2' position, and a methyl group at the 5 position. These modifications provide protection to the cytidine molecule during the synthesis of nucleic acids, preventing unwanted reactions and ensuring the desired product is obtained.

Uses

Used in Synthetic Nucleic Acids Preparation:
N-Benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-O-(2-methoxyethyl)-5-methylcytidine is used as a protected building block for the synthesis of synthetic nucleic acids. The protective groups on the cytidine molecule allow for controlled and selective reactions during the assembly of nucleic acid sequences, ensuring the integrity and stability of the final product. N-Benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-O-(2-methoxyethyl)-5-methylcytidine is particularly useful in the development of modified nucleic acids with enhanced properties, such as increased stability, improved binding affinity, or altered biological activity.

Upstream product

• 93-97-0 benzoic acid anhydride 
• 182496-00-0 2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine 
• 22423-26-3 O-2,2'-cyclo-5-methyluridine 
• 40615-36-9 4,4'-dimethoxytrityl chloride 
• 163759-49-7 2'-O-(2-methoxyethyl)-5-methyluridine 
• 163759-50-0 5'-O-(4,4'-dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-5-methyluridine 
• 256223-97-9 5'-O-(dimethoxytrityl)-3'-O-(2-methoxyethyl)5-methyl cytidine 
• 144-55-8 sodium hydrogencarbonate 
• 40615-35-8 4,4'-dimethoxytrityl alcohol 
• 340162-93-8 N⁴-benzoyl-2’-O-methoxyethyl-5-methylcytidine 
• 100-66-3 methoxybenzene 
• 98-07-7 Benzotrichlorid 

Downstream Products

• 163759-94-2 MOE 5-Me-C Amidite 
• 182496-00-0 2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine 
• 1536203-21-0 C₃₈H₄₅N₃O₉ 
• 1536199-94-6 C₅₀H₅₉N₄O₁₀P 
• 1536204-27-9 C₄₅H₄₇N₃O₁₂*C₆H₁₅N 
• 340162-93-8 N⁴-benzoyl-2’-O-methoxyethyl-5-methylcytidine 

Relevant articles and documents

Copper(II)nitrate catalyzed regioselective protection of primary alcohols with 4,4′-dimethoxytrityl and 2,7-dimethyl-9-phenyl xanthen-9-yl groups in nucleosides and carbohydrates

Regioselective protection of primary hydroxyl group in nucleoside and carbohydrate analogs was accomplished using dimethoxytrityl alcohol (DMTr-OH) or dimethylpixyl alcohol (DMPx-OH) in presence of copper(II)nitrate as a Lewis acid catalyst. Excellent selectivity was observed for the protection of primary hydroxyl group over secondary while glycosidic bond remain unaffected. Utility of this methodology was further exemplified via DMTr- and DMPx-protection of alipahtic acyclic and cyclic diols.

EFFECTS OF APOLIPOPROTEIN B INHIBITION ON GENE EXPRESSION PROFILES IN ANIMALS

Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided. Methods are provided for modulating the expression of genes involved in lipid metabolism, useful in the treatment of conditions associated with cardiovascular risk. Antisense oligonucleotides targeted to apolipoprotein B reduce the level of apolipoprotein B mRNA, lower serum cholesterol and shift liver gene expression profiles from those of an obese animal towards those of a lean animal. Further provided are methods for improving the cardiovascular risk of a subject through antisense inhibition of apolipoprotein B. Also provided are methods for employing antisense oligonucleotides targeted to apolipoprotein B to modulate a cellular pathway or metabolic process.

Antisense modulation of PTP1B expression

Compositions and methods are provided for decreasing blood glucose levels in an animal or for preventing or delaying the onset of a rise in blood glucose levels in an animal, comprising administering to said animal an antisense inhibitor of PTP1B expression in combination with at least one glucose-lowering drug. The present invention is also directed to compositions and methods for improving insulin sensitivity in an animal or for preventing or delaying the onset of insulin resistance in an animal. Also provided are compositions and methods for treating or preventing a metabolic condition in an animal. The metabolic condition may be, e.g., diabetes or obesity.